Newsroom | 46284 results

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ : ONC ; HKEX : 06160 ; SSE : 688235), une société mondiale d'oncologie, annonce aujourd'hui les résultats financiers et les mises à jour d'entreprise du deuxième trimestre 2025. « Notre solide performance au deuxième trimestre renforce notre trajectoire en tant que puissance mondiale en oncologie et souligne notre capacité avérée à générer une croissance durable et à long terme », déclare John V. Oyler, cofondateur, président du...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective August 5th, 2025, to three non-executive employees of non-qualified stock...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235)今天公布了2025年第二季的財務業績和公司最新進展。 BeOne共同創辦人、董事長兼執行長John V. Oyler表示：「第二季的強勁表現印證了我們身為全球腫瘤巨擘的發展軌跡，也彰顯了我們實現永續長期成長的可靠能力。我們正有的放矢地推進策略執行，踐行為全球更多病患提供變革性藥物的使命。BRUKINSA是我們血液腫瘤產品線的主打產品，憑藉最多的獲准適應症和在美國市場的領先地位，持續樹立BTK抑制劑的產業標竿——這一地位源於其在5項適應症中展現的卓越療效、良好安全性及積極的病患預後。在此基礎上，我們另外兩款處於第三期階段的血液腫瘤資產——BCL2抑制劑sonrotoclax和BTK CDAC BGB-16673——可望透過關鍵資料讀出和將於近期啟動的新試驗，進一步擴大我們在該領域的領先優勢。在近期的投資人研發日上，我們規劃了未來18個月內超過20項預期研發里程碑的宏偉路徑。這其中包括在...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a corporate update. “We had another productive quarter, advancing key programs across our pipeline,” said Shawn Singh, Presid...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Reports Q2 2025 Business Results & Initiation of a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations. “This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first twice-yearly HIV prevention option,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio. As we enter...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2025. “We continue to make meaningful progress in our ADI-001 autoimmune Phase 1 clinical program. Site activation is progressing well with more than 20 sites currently open for...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 s...

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “The recent expansion of our T...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the second quarter ending June 30, 2025. “The second quarter of 2025 marked an important inflection point for Rocket as we refined our strategic focus around our AAV cardiovascular gene therapy platform and took m...